期刊文献+

炎敌油用于希罗达治疗乳腺癌所致手足综合征的疗效观察 被引量:6

Clinical efficacy of Yan-Di-Oil on hand-foot syndrome induced by xeloda treating breast cancer
下载PDF
导出
摘要 目的观察炎敌油用于希罗达(卡培他滨)治疗乳腺癌所致手足综合征的临床疗效。方法采用病例对照研究的方法,选择53例乳腺癌口服希罗达患者,随机分为实验组29例和对照组24例。对照组口服希罗达同时给予常规护理及口服维生素B6,实验组在常规护理的基础上同时涂抹炎敌油。观察两组手足综合征的发生情况。结果实验组手足综合征的发生率为34.5%,对照组为58.3%,两组比较差异有统计学意义(P<0.05)。结论炎敌油对防治口服希罗达所致手足综合征有一定的疗效。 Objective To observe the clinical efficacy of Yan-Di-Oil on hand-foot syndrome caused by xeloda(capecitabine tablets)treating breast cancer.Methods 53 patients with breast cancer treated by xeloda were randomly divided into treatment group(n=29)and control group(n=24).Patients in control group took xeloda and routine nursing and vitamin B6,treatment group was given Yan-Di-Oil on the basis of the routine nuring.The occurrence of hand-foot syndrome of both groups was observed.Results The incidence rates of hand-foot syndrome of treatment group and control sroup were 34.5% and 58.3% respectively,there was significant difference between the two groups(P0.05).Conclusion Yan-Di-Oil has certain curative effect on hand-foot syndrome caused by taking xeloda orally.
作者 王阳 陈浩眑
出处 《实用药物与临床》 CAS 2013年第7期650-651,共2页 Practical Pharmacy and Clinical Remedies
关键词 希罗达 手足综合征 炎敌油 Xeloda Hand-foot syndrome Yan-Di-Oil
  • 相关文献

参考文献5

二级参考文献12

  • 1戚宝婵,武微奈.炎敌油质量标准的研究[J].中成药,1996,18(2):16-17. 被引量:6
  • 2Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer.J Clin Oncol, 1999,17:485-493.
  • 3Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002,86:1367-1372.
  • 4Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, Phase Ⅱ study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 2001,92:1759-1768.
  • 5Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase Ⅱ study of oral capecitabine (Xeloda('')) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol, 2003,14:1227-1233.
  • 6Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecita-bine: a single-institution experience. Cancer Invest, 2002,20:3-10.
  • 7Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology, 2002,16:31-37.
  • 8McMurrough J, McLeod HL. Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmacol, 1996,41:425-427.
  • 9叶任高,陆再英,张珍祥,等.内科学[M].第6版.北京:人民卫生出版社,2003.57-63.
  • 10Apelqvist J,Bakker K, VanHoutum WH, et al.International consensus and practial guidelines on the managent and the prevention of the diabetic foot.International Working Gorking Group on the Diabetic Foot[J].Diabetes Metab Res Rew,2000,16(S1): 84~92

共引文献69

同被引文献61

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部